Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up.
Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up.
复制标题
DOI：
10.1002/hep.23219
复制
发表时间：
2009-10
期刊：
影响因子：
13.5
通讯作者：
Chung, Raymond T.
中科院分区：
文献类型：
--
作者：
Corey, Kathleen E.;Kane, Erin;Munroe, Craig;Barlow, Lydia L.;Zheng, Hui;Chung, Raymond T.
欧洲和非洲的研究已经证实了丙型肝炎相关的低脂血症。在2项相关研究中，我们评估了美国队列中丙型肝炎感染和治疗与血脂水平之间的关系，并确定了临床显著的治疗后高脂血症的频率。对丙型肝炎患者和非丙型肝炎患者进行病例对照分析。丙型肝炎组由179名感染者组成。未感染对照组由180名年龄匹配的对照组成。比较空腹胆固醇、低密度脂蛋白（LDL）、高密度脂蛋白和甘油三酯。第二组是一个回顾性队列（治疗丙型肝炎组）的87例治疗前和治疗后的血脂数据的丙型肝炎患者。在病例对照分析中，丙型肝炎组的LDL和胆固醇显著低于未感染的对照组。在回顾性队列中，与未清除病毒的患者相比，接受治疗的丙型肝炎组中实现病毒清除的患者的LDL和胆固醇较基线升高。这些结果在调整年龄、性别和基因型后仍然存在。13%的病毒清除患者LDL升高，33%的患者胆固醇升高至无法接受降脂治疗的水平。丙型肝炎与胆固醇和LDL水平降低有关。这种低血脂症随着成功的丙型肝炎治疗而消退，但在无应答者中持续存在。相当一部分成功治疗的患者经历LDL和胆固醇反弹至与增加的冠状动脉疾病风险相关的水平。接受抗病毒治疗的人应仔细监测血脂。
Hepatitis C associated hypolipidemia has been demonstrated in studies from Europe and Africa. In 2 linked studies we evaluated the relationship between hepatitis C infection and treatment with lipid levels in an American cohort and determined the frequency of clinically significant post-treatment hyperlipidemia. A case-control analysis of patients with and without hepatitis C was performed. The Hepatitis C Group consisted of 179 infected patients. The Uninfected Control Group consisted of 180 age matched controls. Fasting cholesterol, low density lipoprotein (LDL), high density lipoprotein and triglycerides were compared. The second group was a retrospective cohort (Treated Hepatitis C Group) of 87 treated Hepatitis C patients with lipid data before and after therapy. In the case-control analysis, the Hepatitis C Group had significantly lower LDL and cholesterol than the Uninfected Control Group. In the retrospective cohort, patients in the Treated Hepatitis C Group who achieved viral clearance had increased LDL and cholesterol from baseline compared to patients without viral clearance. These results persisted when adjusted for age, sex and genotype. 13% of patients with viral clearance had increased LDL and 33% experienced increases in cholesterol to levels warranting lipid lowering therapy. Hepatitis C is associated with decreased cholesterol and LDL levels. This hypolipidemia resolves with successful hepatitis C treatment but persists in non-responders. A significant portion of successfully treated patients experience LDL and cholesterol rebound to levels associated with increased coronary disease risk. Lipids should be carefully monitored in persons receiving antiviral therapy.
登录
查看更多内容
影响因子：
56.9
作者：
BROWN, MS;GOLDSTEIN, JL
通讯作者：
GOLDSTEIN, JL
影响因子：
13.5
作者：
Gopal, Kavitha;Johnson, Timothy C.;Min, Albert D.
通讯作者：
Min, Albert D.
影响因子：
4.9
作者：
Floris-Moore, Michelle;Howard, Andrea A.;Klein, Robert S.
通讯作者：
Klein, Robert S.
影响因子：
3.8
作者：
Diaz, Olivier;Delers, Francois;Andre, Patrice
通讯作者：
Andre, Patrice
影响因子：
120.7
作者：
STAMLER, J;WENTWORTH, D;NEATON, JD
通讯作者：
NEATON, JD